AGTR1 and endothelial dysfunction: Accordingly, inhibitors of the RAS, including the antagonists for the angiotensin II type 1 receptor (AT1R), appear effective at protecting against endothelial dysfunction in clinical studies [6] as well as endothelial inflammation in preclinical studies [5,7].